Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials-Reference-Cited by-同舟云学术

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials

Published:2020-08-10 Issue:11 Volume:27 Page:1222-1233
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Nangia Gayatri¹,Vierling John M.²,Kwo Paul³,Brown Deborah D.⁴,Klopfer Stephanie O.⁴,Robertson Michael N.⁴,Haber Barbara A.⁴,Reddy K. Rajender¹^ORCID

Affiliation:

1. Department of Medicine Division of Gastroenterology and Hepatology University of Pennsylvania Philadelphia PA USA

2. Departments of Medicine and Surgery Baylor College of Medicine Houston TX USA

3. Department of Medicine—Gastroenterology and Hepatology Stanford University School of Medicine Palo Alto CA USA

4. Merck & Co., Inc. Kenilworth NJ USA

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13357

Reference24 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

2. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy

3. EASL Recommendations on Treatment of Hepatitis C 2018

4. US Food and Drug Administration. Safety Announcement. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret Zepatier and Vosevi in some patients with advanced liver disease. August 28 2019. Accessed November 25 2019.https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐warns‐about‐rare‐occurrence‐serious‐liver‐injury‐use‐hepatitis‐c‐medicines‐mavyret‐zepatier‐and.)

5. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study;Hepatology Communications;2023-02-14

2. Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug–Drug Interactions with Antiviral Treatments for Hepatitis C;Pathogens;2021-05-24

3. Elbasvir and grazoprevir for the treatment of hepatitis C;Expert Review of Anti-infective Therapy;2021-01-17